EcoDrugPlus

Macrophage Migration Inhibitory Factor

Ensembl ID : ENSATEG00000011925
Gene Symbol: MIF
2 Cross references
235 Possible Orthologues:

Macrophage Stimulating 1 Receptor B

Ensembl ID : ENSATEG00000009407
Gene Symbol: MST1RB
2 Cross references
194 Possible Orthologues:

Macrophage-Stimulating Protein Receptor-Like

Ensembl ID : ENSATEG00000024714
Gene Symbol: LOC113154399
2 Cross references
196 Possible Orthologues:

Matrix Metallopeptidase 14a (Membrane-Inserted)

Ensembl ID : ENSATEG00000001619
Gene Symbol: MMP14A
3 Cross references
199 Possible Orthologues:

Matrix Metallopeptidase 14b (Membrane-Inserted)

Ensembl ID : ENSATEG00000007310
Gene Symbol: MMP14B
3 Cross references
198 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSATEG00000002575
Gene Symbol: MMP2
3 Cross references
210 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSATEG00000020195
Gene Symbol: MMP9
3 Cross references
216 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSATEG00000004175
Gene Symbol: MTOR
2 Cross references
222 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSATEG00000001166
Gene Symbol: MC1R
3 Cross references
159 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSATEG00000021918
Gene Symbol: MC4R
3 Cross references
211 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSATEG00000016090
Gene Symbol: LOC113163507
2 Cross references
212 Possible Orthologues:

Melatonin Receptor 1a A

Ensembl ID : ENSATEG00000010218
Gene Symbol: MTNR1AA
1 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).